Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Clearmind Medicine Inc
(NQ:
CMND
)
1.300
+0.080 (+6.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Clearmind Medicine Inc
< Previous
1
2
3
4
5
6
Next >
Why National CineMedia Shares Are Trading Higher By Around 111%; Here Are 20 Stocks Moving Premarket
April 11, 2023
Gainers National CineMedia, Inc. (NASDAQ: NCMI) jumped 111.2% to $0.2810 in pre-market trading after a 13G filing showed a 9.1% passive stake in the company from AMC Entertainment.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 11, 2023
We're starting off the day with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on Tuesday!
Via
InvestorPlace
How To Finance A Psychedelics Business? Learn From These Four Companies
April 04, 2023
Clearmind Medicine Announces Pricing of $3.5 Million Public Offering
Via
Benzinga
Dow Tumbles Over 200 Points; Butterfly Network Shares Spike Higher
April 04, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 200 points on Tuesday. The Dow traded down 0.64% to 33,387.61 while the NASDAQ fell 0.45% to 12,134.09. The S&P...
Via
Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 04, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.
Via
Benzinga
Gold Rises Sharply; AMC Entertainment Shares Plunge
April 04, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 150 points on Tuesday. The Dow traded down 0.46% to 33,447.10 while the NASDAQ fell 0.30% to 12,152.44. The S&P 500,...
Via
Benzinga
Why Clearmind Medicine Shares Are Nosediving
April 04, 2023
Clearmind Medicine Inc (NASDAQ: CMND) shares are trading lower by 60.1% to $0.57 Tuesday morning after the company announced a $3.5 million public offering priced at $0.78 per share. The offering is...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
April 04, 2023
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all the latest news traders need to know about!
Via
InvestorPlace
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered
Via
Benzinga
A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next
March 17, 2023
Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial...
Via
Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 13, 2023
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.
Via
Benzinga
US Stocks Mostly Higher; Dow Rises 75 Points
March 13, 2023
U.S. stocks traded mostly higher this morning, with the Dow Jones gaining around 75 points on Monday. Following the market opening Monday, the Dow traded up 0.24% to 31,986.55 while the NASDAQ rose...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
March 13, 2023
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday!
Via
InvestorPlace
Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
March 06, 2023
After everything that's happened in the last several years, we believe it's safe to say that the psychedelic renaissance is a reality, one that Benzinga has consistently reported on.
Via
Benzinga
Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More
February 27, 2023
Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...
Via
Benzinga
SciSparc And Clearmind Reveal Three Unique Combinations Of Future Psychedelic-Based Compounds
February 22, 2023
SciSparc Ltd. (NASDAQ: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that as part of its...
Via
Benzinga
Novel Combination Of Cannabis-Like Compound With Classical Psychedelics Searches IP Coverage In US
February 15, 2023
Israeli-based next-gen psychedelics biotech Clearmind Medicine (NASDAQ: CMND) together with partner clinical-stage pharma company SciSparc (NASDAQ: SPRC) has filed three provisional patent applications...
Via
Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - The Road Ahead
February 01, 2023
(Part four of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results
January 31, 2023
Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained...
Via
Benzinga
Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More
January 25, 2023
Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First?
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 25, 2023
It's time to start off the day with an overview of the biggest pre-market stock movers traders need to know about on Wednesday!
Via
InvestorPlace
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
January 24, 2023
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
EXCLUSIVE: Next-Generation Psychedelics, MEAI - How And Why, An Israeli Scientist Explains
January 23, 2023
(This is part two of a four-part series) Check out part one in the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Via
Benzinga
Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
January 20, 2023
(Part one of a four-part series) Increasing evidence of psychedelics’ potential for benefiting both mental and physical health conditions are moving biotech companies and scientists in the sector to...
Via
Benzinga
Clearmind Teams With Yissum, University of Jerusalem On 2 Psychedelic R&D Projects
January 19, 2023
Psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) has successfully completed two drug discovery projects with leading scientists at the Hebrew University of Jerusalem.
Via
Benzinga
Envisioning A Cocaine-Addiction Treatment: This Next-Gen Psychedelic Shows Positive Results
January 18, 2023
Israel-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) shared additional positive results on the impact of the MEAI molecule in the natural reward process in an in-vivo preclinical...
Via
Benzinga
This Original Psychedelic-Based Obesity Treatment Set To First-In-Human Trials
January 06, 2023
Psychedelics biopharma company Clearmind Medicine Inc. (NASDAQ: CMND) and clinical-stage firm SciSparc Ltd.
Via
Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
January 03, 2023
What a year for psychedelics!
Via
Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Israeli Psychedelics Biotech Shares Latest Advancements, Moves Forward With Addictions Treatment
December 19, 2022
Psychedelics company Clearmind Medicine Inc. (NASDAQ: CMND) aims to bring its proprietary compound, CMND-100, to clinical trials while developing additional proprietary psychedelic compounds for...
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.